SCHEMBL3484447

SCHEMBL3484447

Nc1ccccc1S(=O)(=O)Nc1ccc(C(=O)/C=C/c2ccc(O)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 2/20 0.54
MAOB P27338 3/20 0.53
CYP3A4 P08684 2/20 0.53
HSPD1 P10809 2/20 0.53
HSPE1 P61604 2/20 0.53
KMT2A Q03164 2/20 0.53
RAB9A P51151 2/20 0.53
MAPT P10636 2/20 0.53
MAOA P21397 2/20 0.53
PKM P14618 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
MEN1 O00255 1/20 0.53
ALDH2 P05091 1/20 0.53
CYP19A1 P11511 1/20 0.53
CYP1B1 Q16678 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
HDAC1 Q13547 3/20 0.52
P4HB P07237 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484449 1.00 F3 (0.54) F3MAOBCYP3A4HSPD1HSPE1
SCHEMBL30384281 1.00 F3 (0.54) F3MAOBCYP3A4HSPD1HSPE1
SCHEMBL30383045 0.88 MAPT (0.52) KMT2AMAPTMEN1P4HBCXCL12
SCHEMBL3484359 0.88 MAPT (0.52) KMT2AMAPTMEN1P4HBCXCL12
SCHEMBL3484356 0.88 MAPT (0.52) KMT2AMAPTMEN1P4HBCXCL12
SCHEMBL25197330 0.86 ESR1 (0.54) F3MAOBCYP3A4HSPD1HSPE1
SCHEMBL3484363 0.86 F3 (0.54) F3MAOBCYP3A4HSPD1HSPE1
SCHEMBL25190825 0.86 MAPT (0.54) F3MAOBCYP3A4HSPD1HSPE1
SCHEMBL3484366 0.86 F3 (0.54) F3MAOBCYP3A4HSPD1HSPE1
SCHEMBL25195314 0.86 MAOB (0.54) F3MAOBCYP3A4HSPD1HSPE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP claimed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US claimed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP claimed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US claimed
EP-2099440-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS Seoul National University Industry Foundation (KR) 2009-09-16 EP claimed
WO-2008069608-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) 2008-06-12 WO claimed
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP disclosed
US-9072698-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2015-07-07 US disclosed
US-9072698-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2015-07-07 US disclosed
US-9072698-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2015-07-07 US disclosed
US-9057725-B2 Composition for diagnosing, treating, and preventing liver disease SNU R&DB FOUNDATION (KR) 2015-06-16 US disclosed
US-9057725-B2 Composition for diagnosing, treating, and preventing liver disease SNU R&DB FOUNDATION (KR) 2015-06-16 US disclosed
US-9057725-B2 Composition for diagnosing, treating, and preventing liver disease SNU R&DB FOUNDATION (KR) 2015-06-16 US disclosed
US-20120282619-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY 2012-11-08 US disclosed
US-20120282619-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY 2012-11-08 US disclosed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US disclosed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US disclosed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US disclosed
EP-2099440-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS Seoul National University Industry Foundation (KR) 2009-09-16 EP disclosed
WO-2008069608-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS TM9SF4, TM9SF2, TM9SF3 F3 170/4885MAOB 4763/4885CYP3A4 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.